Christopher Kramer MD (@chriskramermd) 's Twitter Profile
Christopher Kramer MD

@chriskramermd

Chief, CV Division and George Beller Professor, UVA. CV Imager. VP, ACC. Husband, proud dad of an actor/PAC director and a sales specialist. Tweets my own.

ID: 4844807429

calendar_today25-01-2016 08:50:15

1,1K Tweet

3,3K Followers

1,1K Following

Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 (@drmarthagulati) 's Twitter Profile Photo

#AHA24 Characteristics of the #SUMMIT population #LBCT 🫀 women enrolled! 👏🏽 🫀QoL by KCCQ improved greater in the treatment arm 🫀endpoint driven by ⤵️ HF worsening in Tx arm 🫀⤵️ in primary endpoint achieved with HR=0.62, p=0.026 This was an outcomes trial for #HFpEF NEJM

#AHA24
Characteristics of the #SUMMIT population #LBCT 
🫀 women enrolled! 👏🏽
🫀QoL by KCCQ improved greater in the treatment arm
🫀endpoint driven by ⤵️ HF worsening in Tx arm 
🫀⤵️ in primary endpoint achieved with HR=0.62, p=0.026
This was an outcomes trial for #HFpEF 
<a href="/NEJM/">NEJM</a>
American College of Cardiology (@accintouch) 's Twitter Profile Photo

SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening #heartfailure events & improved #QoL in patients w/ #HFpEF & obesity. “Cardiologists now have an ever-expanding armamentarium to treat HFpEF,” says Dr. Christopher Kramer MD. bit.ly/4hSxZ9J

SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening #heartfailure events &amp; improved #QoL in patients w/ #HFpEF &amp; obesity. “Cardiologists now have an ever-expanding armamentarium to treat HFpEF,” says Dr. <a href="/ChrisKramerMD/">Christopher Kramer MD</a>. bit.ly/4hSxZ9J
American College of Cardiology (@accintouch) 's Twitter Profile Photo

Drs Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT and Christopher Kramer MD share the new #CVBoard of Medicine’s vision for evaluating clinical expertise, demonstrating continuous clinical and professional competence and ultimately providing value to clinicians and patients. Learn more about the Board at

Drs <a href="/RBP0612/">Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT</a> and <a href="/ChrisKramerMD/">Christopher Kramer MD</a> share the new #CVBoard of Medicine’s vision for evaluating clinical expertise, demonstrating continuous clinical and professional competence and ultimately providing value to clinicians and patients. Learn more about the Board at
NEJM (@nejm) 's Twitter Profile Photo

Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) nej.md/4hRGaTY #AHA24 | AHA Science

Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) nej.md/4hRGaTY 

#AHA24 | <a href="/AHAScience/">AHA Science</a>
JACC Journals (@jaccjournals) 's Twitter Profile Photo

#AHA24: In the #CMR substudy of the #SUMMIT trial, Dr. Christopher Kramer MD & team in #JACC show that tirzepatide decreased LV mass and paracardiac adipose tissue - a potential mechanism for reduced #heartfailure events bit.ly/3CytSPZ #Obesity

#AHA24: In the #CMR substudy of the #SUMMIT trial, Dr. <a href="/ChrisKramerMD/">Christopher Kramer MD</a> &amp; team in #JACC show that tirzepatide decreased LV mass and paracardiac adipose tissue - a potential mechanism for reduced #heartfailure events bit.ly/3CytSPZ #Obesity
Ritu Thamman MD (@iamritu) 's Twitter Profile Photo

Christopher Kramer MD #AHA24 #SUMMIT #WhyCMR substudy on BNP deficiency subset of HFpEF 106 pts (Tirzepatide 50 🆚 placebo 56) mostly in 🇦🇷 🇧🇷 Finds ⬇️LV mass(11 Gm) linear to weight loss ⬇️ adipose tissue pericardial not epicardial bit.ly/4hXoCpd

<a href="/ChrisKramerMD/">Christopher Kramer MD</a> #AHA24
#SUMMIT #WhyCMR substudy on BNP deficiency subset of HFpEF  
106 pts (Tirzepatide 50 🆚 placebo 56) mostly in 🇦🇷 🇧🇷 
Finds
⬇️LV mass(11 Gm)  linear to weight loss
⬇️ adipose tissue pericardial not epicardial 
bit.ly/4hXoCpd
Henry Han (@hancardiomd) 's Twitter Profile Photo

In #SUMMIT substudy of tirzepatide for obesity-related HFpEF (n=175): 📍Primary outcome: LV mass ⬇️ by 11 g (95% CI: −19 to −4 g) in the treatment group vs placebo (P=0.004). 📍Paracardiac fat: ⬇️ by 45 mL (95% CI: −69 to −22 mL) in the treatment group (P<0.001). 📍LV mass

In #SUMMIT substudy of tirzepatide for obesity-related HFpEF (n=175):

📍Primary outcome: LV mass ⬇️ by 11 g (95% CI: −19 to −4 g) in the treatment group vs placebo (P=0.004).

📍Paracardiac fat: ⬇️ by 45 mL (95% CI: −69 to −22 mL) in the treatment group (P&lt;0.001).

📍LV mass
Harlan Krumholz (@hmkyale) 's Twitter Profile Photo

5/ Key takeaway: Tirzepatide offers a novel approach to reduce cardiac stress and adiposity in obesity-related HFpEF - and it improves outcomes. Substudy led by Christopher Kramer MD. JACC Journals Read the full study: jacc.org/doi/10.1016/j.…

CardioNerds Journal Club (@cardionerdsjc) 's Twitter Profile Photo

Check out this fantastic infographic by Sahi Allam, MD summarizing key points from SEQUOIA-HCM below ⤵️ and remember to join us tonight on X at 8PM for a live discussion with experts! Follow along with #CardsJC for the discussion!

Check out this fantastic infographic by <a href="/SahiAllam/">Sahi Allam, MD</a> summarizing key points from SEQUOIA-HCM below ⤵️ and remember to join us tonight on X at 8PM for a live discussion with experts! Follow along with #CardsJC for the discussion!
Christopher Kramer MD (@chriskramermd) 's Twitter Profile Photo

Happening this evening! Join Milton Packer MD, me, and the JACC editors for the inaugural JACC journal club on the SUMMIT trial and CMR substudy.

UVA Department of Medicine (@uvadom) 's Twitter Profile Photo

cbs19news.com/news/researche… UVA Health researcher Dr. Christopher Kramer explains how a weight-loss drug can reduce the risk of death from heart failure. UVA Cardio UVA Cardiology Fellowship Christopher Kramer MD #UVACardio #UVAMedicine #UVADoM #UVADeptOfMedicine

Scott Isaacs (@scottisaacsmd) 's Twitter Profile Photo

A substudy of the SUMMIT trial using cardiac MRI demonstrated that tirzepatide in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss. #tirzepatide #HFpEF jacc.org/doi/10.1016/j.…

A substudy of the SUMMIT trial using cardiac MRI demonstrated that tirzepatide in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss. #tirzepatide #HFpEF 
jacc.org/doi/10.1016/j.…